Alectinib after surgery for early ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how well alectinib works when given after surgery to people with early-stage ALK-positive non-small cell lung cancer. It aims to understand real-world outcomes for patients who take this targeted therapy as their first treatment after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stage II, IIIA, or selected IIIB non-small cell lung cancer (NSCLC).
- Your tumor tests positive for a gene change called ALK.
- You had surgery to completely remove the lung cancer.
- You have started taking alectinib as your first treatment after surgery, within the last 28 days.
- You have not had any other cancer treatment before alectinib (like chemotherapy or other targeted pills).
- You are not pregnant, breastfeeding, or planning to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares the usual dose of alectinib with a modified dose chosen by checking alectinib blood levels. It aims to see whether adjusting the dose based on blood testing can work as well (and possibly be better tolerated) for people with ALK-positive non-small cell lung cancer.
This early-phase trial studies how alectinib (an ALK-blocking medicine) moves through the body and how it’s tolerated in people with advanced non-small cell lung cancer (NSCLC) that has an ALK rearrangement. You may be considered if you have ALK-positive, recurrent or advanced disease and have already had specific prior treatments.
This trial tests whether giving alectinib (a targeted drug) combined with chemotherapy before surgery can help people with stage III ALK-positive lung cancer that cannot be removed surgically. The goal is to shrink the tumor enough to make surgery possible and improve long-term outcomes.
This trial tests giving alectinib first, then adding targeted radiation to remaining spots of cancer in people with ALK-rearranged advanced non-small cell lung cancer. It aims to control the cancer after an initial response and help keep disease from progressing.
This study tests whether alectinib can treat ALK-positive cancers in adults, teenagers, and children. It focuses on people whose cancer testing shows an ALK change, and who can start oral treatment and have a new tissue sample.
This Phase 2 trial tests pembrolizumab (an immune therapy), bevacizumab (a medicine that blocks blood-vessel growth), and chemotherapy in people with ALK-rearranged lung cancer that is still present after the first treatment with alectinib. It aims to shrink tumors and improve control of the cancer.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.